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Abstract
Neuropeptide S (NPS) and its receptor (NPSR) have been implicated in the mediation of anxiolytic-like
behaviour in rodents. However, little knowledge is available regarding the NPS system in depression-
related behaviours, and whether NPS also exerts anxiolytic eﬀects in an animal model of psycho-
pathology. Therefore, the aim of this work was to characterize the eﬀects of NPS on depression- and
anxiety-related parameters, using male and female rats in a well-validated animal model of depression :
the Flinders Sensitive Line (FSL), their controls, the Flinders Resistant Line (FRL), and Sprague–Dawley
(SD) rats. We found that FSL showed greater immobility in the forced swim test (FST) than FRL,
conﬁrming their phenotype. However, NPS did not aﬀect depression-related behaviour in any rat line.
No signiﬁcant diﬀerences in baseline anxiety levels between the FSL and FRL strains were observed, but
FSL and FRL rats displayed less anxiety-like behaviour compared to SD rats. NPS decreased anxiety-like
behaviour on the elevated plus-maze in all strains. The expression of the NPSR in the amygdala, peri-
ventricular hypothalamic nucleus, and hippocampus was equal in all male strains, although a trend
towards reduced expression within the amygdala was observed in FSL rats compared to SD rats. In
conclusion, NPS had a marked anxiolytic eﬀect in FSL, FRL and SD rats, but did not modify the
depression-related behaviour in any strain, in spite of the signiﬁcant diﬀerences in innate level between
the strains. These ﬁndings suggest that NPS speciﬁcally modiﬁes anxiety behaviour but cannot overcome/
reverse a genetically mediated depression phenotype.
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Introduction
Aﬀective disorders belong to the diseases causing
most chronic suﬀering and a major cause of suicide,
while anxiety disorders belong to the most prevalent.
In a recently published report with data from WHO
Mental Health surveys, the days in which the study
subjects were unable to normally perform their daily
activities (days out of role) were assessed (Alonso et al.
2010). Psychiatric disorders, such as depression, bi-
polar disorder and anxiety disorders, accounted for a
signiﬁcant proportion of all days out of role. Together
with the WHO Global Burden of Disease report
(WHO, 2004), this highlights the severity of the prob-
lem, and prompts the search for novel strategies in
therapeutics and prophylaxis.
The wide variety of neuropeptide eﬀects in the
regulation of central nervous system (CNS) functions
have, in recent years, been exploited in CNS drug
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development (Chiou et al. 2007; Frank & Landgraf,
2008 ; Ring, 2005 ; Valdez, 2006 ; Varty et al. 2003).
Thus, peptide receptors may constitute relevant drug
targets for neuropsychiatric disorders, as exempliﬁed
by neurotensin receptor agonists in schizophrenia
(Boules et al. 2007; Kinkead & Nemeroﬀ, 2006) and
corticotropin-releasing factor 1 or vasopressin receptor
antagonists in depression and anxiety (Frank &
Landgraf, 2008 ; Nielsen, 2006).
Recently, the receptor for a previously unknown,
highly conserved (Reinscheid, 2007), 20-amino-acid
peptide, neuropeptide S (NPS), was implicated in the
regulation of anxiety and wakefulness (Xu et al. 2004).
The orphan G-protein-coupled receptor was identiﬁed
as the cognate NPS receptor (NPSR) (Mori et al. 2002).
NPS acts as a NPSR agonist, increasing intracellular
calcium and accumulation of cyclic adenosine mono-
phosphate (cAMP) (Gupte et al. 2004; Xu et al. 2004).
In rodents, current evidence supports the existence
of one NPSR (in contrast to the eight described human
variants ; Vendelin et al. 2005) that exhibits a high
sequence similarity to the human hNPSR-A variant
(Pulkkinen et al. 2006). In humans, a naturally occur-
ring polymorphism, NPSR A/T (Asn107Ile), in the
NPSR has been described to result in an enhanced
intracellular Ca2+ and cAMP signal transduction,
which may be relevant in human asthma (Reinscheid
et al. 2005). In a recently published study, the same
polymorphism has been observed to have a role in
panic disorder, proposed to be mediated through a
heightened autonomic arousal and distorted process-
ing of anxiety-relevant emotional stimuli (Domschke
et al. 2010). Further, in an association analysis of gen-
etic variants in NPS and NPSR1 in three independent
study samples, NPSR1 was associated with panic
disorder diagnosis and with parent-reported anxiety/
depression (Donner et al. 2010). Similarly, carriers
of the NPSR1T allele have been associated with over-
interpretation of fear reactions (Raczka et al. 2010).
The mRNA encoding NPSR are expressed at high
levels in several regions of the CNS, e.g. thalamus,
hypothalamus, and amygdala (Leonard & Ring, 2011;
Xu et al. 2004, 2007). Based on this distribution, NPS
was proposed to be involved in arousal, regulation of
food intake, and anxiety (Beck et al. 2005; Smith et al.
2006; Xu et al. 2004). These roles have been supported
by behavioural studies, where centrally administered
NPS decreases sleep, increases wakefulness (Xu et al.
2004), reduces food intake (Beck et al. 2005; Smith
et al. 2006), and anxiety-related behaviours (Vitale et al.
2008; Xu et al. 2004). Consistent with these obser-
vations, NPS and NPSR have also been implicated in
learning and memory (Meis et al. 2008). NPS also
facilitates extinction of conditioned fear responses in
an auditory-cued paradigm when administered into
the amygdala in mice (Jungling et al. 2008). Further-
more, NPSR-deﬁcient mice show signiﬁcant deﬁcits
in inhibitory avoidance test compared to controls
(Duangdao et al. 2009).
The role of NPS in depression-like behaviour has
not been intensively investigated. However, central
administration of NPS to mice did not show a pro-
nounced eﬀect in the tail suspension test (TST;
Leonard et al. 2008) or forced swim test (FST; Guerrini
et al. 2009). Depression is linked to cognitive deﬁcits
(Fossati et al. 1999, 2002 ; Harvey et al. 2004) and, in-
terestingly, NPS improves cognitive performance in
the novel object recognition task in mice (Duangdao
et al. 2009) and facilitates spatial memory in the
Morris water maze, when injected supraspinally
(Li et al. 2009).
While the data from human polymorphism studies
suggest that the NPS system may be involved in the
aetiology of anxiety and depression, all the animal
experimental ﬁndings are from ‘normal’ rodents thus
making it diﬃcult to draw translational conclusions.
Consequently, we decided to test eﬀects of NPS in a
rodent model of depression.
The Flinders Sensitive Line (FSL) rat is a highly
validated genetic animal model of depression
(Overstreet et al. 2005; Wegener et al. in press). These
animals present with exaggerated immobility in the
FST, the prototypical screening procedure for anti-
depressant action and depression-like phenotype in
rodents (Liebenberg et al. 2010; Porsolt et al. 1977,
1978 ; Slattery et al. 2005). Further, FSL animals present
with several of the measurable characteristic features
of ‘clinical ’ depression, as well as increased stress re-
sponsiveness compared to their controls – the Flinders
Resistant Line (FRL) and Sprague–Dawley (SD) rats,
while they also respond to chronic, but not acute,
treatment with antidepressants (Neumann et al. 2010;
Overstreet et al. 2005; Wegener et al. in press). At the
neurobiological level, the FSL rat displays multiple
abnormalities consistent with proposed theories of
depression, in particular altered serotonergic and
cholinergic function as well as decreased expression
of neuropeptide Y (Jimenez Vasquez et al. 2000, 2007;
Mathe´ et al. 2007; Overstreet et al. 2005; Wegener et al.
in press).
In view of the above, the aim of the current study
was to investigate the possible role of NPS in anxiety
and depression-like behaviours in FSL and FRL strains
and an additional control, the SD rats. Therefore, we
determined whether central administration of NPS
diﬀerentially aﬀected these behaviours in FSL, FRL
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and SD rats, and if basal NPSR expression levels in
hippocampus, amygdala, and periventricular hypo-
thalamic nucleus (PVN) could contribute to the FSL
phenotype. Further, we aimed to explore if such
assessments, in a model of depression, could be useful
tools in mapping the biological underpinnings dis-
criminating between anxiety and depression. Finally,
we evaluated possible gender diﬀerences in the be-
haviour measured by assessing the eﬀect of NPS on
female FSL, FRL, and SD animals’ behaviour.
Methods
Animals
Male and female FSL and FRL rats (age 10–12 wk),
from the colony maintained at the University of
Aarhus (originally derived from the colony at the
University of North Carolina, USA) and male and fe-
male SD rats purchased from Taconic A/S (Denmark)
were used. All rats weighed 280–350 g at the start of
experimental procedures, and were cage-housed in-
dividually (Cage 1291H Eurostandard Type III H,
425r266r185 mm, Techniplast, Italy) at 20¡2 xC on
a 12-h light/dark cycle (lights on 07.00 hours). Tap
water and chow pellets were available ad libitum. The
animal colony was protected from outside noise, and
all experimental procedures were performed in spe-
cially equipped rooms within the animal house be-
tween 08:00 and 12:00 hours. All animal procedures
were approved by the Danish National Committee for
Ethics in Animal Experimentation (2007/561-1378).
Drugs
Rat NPS (H-Ser-Phe-Arg-Asn-Gly-Val-Gly-Ser-Gly-
Val-Lys-Lys-Thr-Ser-Phe-Arg-Arg-Ala-Lys-Gln-OH)
triﬂuoroacetate salt (Bachem AG, Switzerland) was
diluted with Ringer’s solution (145 mM Na, 3 mM K+,
1.2 mM Ca2+, 1.0 mM Mg2+, pH adjusted to 7.4) to a
ﬁnal concentration of 0.05, 0.25, 0.5 or 1.0 nmol/5 ml
(Smith et al. 2006). Vehicle animals received a 5 ml
infusion of sterile Ringer’s solution. All drugs were
kept on ice during the experimental procedures.
Drugs were freshly prepared daily from a frozen stock
solution.
Stereotaxic surgery
All surgical procedures were performed under semi-
sterile conditions. Prior to surgery rats were anaes-
thetized with fentanyl/ﬂuanisone (VetaPharma Ltd,
UK; 0.0945/0.3 mg/kg) and midazolam (0.25 mg/kg).
The anaesthetized animals were ﬁxed in a stereotaxic
frame (David Kopf, USA) with the incisor bar set at
x3.3 mm to give a ﬂat skull surface and subsequently
implanted with an intracerebroventricular (i.c.v.)
guide cannula just above the right lateral ventricle
(AP x1.0, L x1.6, DV x1.8, according to Paxinos &
Watson, 1986), ﬁxed with two stainless-steel screws
and dental acrylic (GC Fuju Plus, GC Corp., Japan). A
dummy was inserted into the guide cannula. Follow-
ing surgery, the animals were injected with ampicillin
(100 mg/kg s.c., 0.09 mg/kg buprenorphin s.c.
(Schering-Plough A/S, Denmark) and 0.2 mg/kg
Rimadyl (Pﬁzer A/S, Denmark), and returned to
their home cage for recovery. The rats were monitored
by daily weighing and handling, including removal
of the dummy cannula in order to habituate the ani-
mals to the procedure of later intracerebral injection,
thereby minimizing the stress reaction on the exper-
imental day.
I.c.v. procedure
For the infusion, the upper part of a 25-mm-long 25-
gauge cannula, was inserted into a 45-cm polyamine
tubing (0.38 mm inner diameter, 1.09 mm outer diam-
eter), which in turn was attached to a 25 ml Hamilton
syringe (Hamilton Syringes, Swizerland). The infusion
system was ﬁlled with 5 ml NPS or vehicle, which was
then injected over a period of 1 min and left in place
for 30 s to allow diﬀusion. Injection of NPS or vehicle
was performed 45 min prior to the behavioural testing
and the animal was returned to its home-cage for this
period. Animals were randomly assigned to the sub-
groups and received the same treatment throughout
all experiments.
Elevated plus-maze (EPM)
After a 7-d recovery from surgery, the rats were tested
for anxiety-related behaviour on the EPM. A plus-
shaped maze, elevated 70 cm above the ground, was
constructed from black acrylic and consisted of two
open arms and two closed arms (each lengthrwidth:
50r10 cm), connected by a neutral zone (10r10 cm).
The closed arms were surrounded by 40 cm high
walls, whereas the open arms had only a 0.5 cm high
rim. Light intensity in the open arm was 80–90 lx
whereas it was 20 lx in the closed arm. Behaviour of
the animal on themaze during the 5-min testing period
was monitored by a camera, mounted on the ceiling
above and connected to a computer. The anxiety-
related behaviours, including the percent of entries
into open arms (%OAE) and the percent time spent on
the open arms (%OA), the number of full entries (FE)
into open arms (i.e. number of times the rat spent with
the entire length of its body on the open arm) and
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closed-arm entries (CAE) were subsequently assessed
by an observer blind to the treatment. The number of
entries into the closed arms was used as indicator of
general locomotor activity.
Forced swim test (FST)
Five days after the EPM test the rats were exposed to
the FST as previously described, using a modiﬁed
version of the original protocol deﬁned by Porsolt
(Liebenberg et al. 2010; Porsolt et al. 1977, 1978;
Slattery et al. 2005). Animals were subjected to a
15-min pre-swim and 24 h later a 5-min test session in
a perspex cylinder (height 60 cm, diameter 24 cm) ﬁlled
with water (25 xC) to a height of 40 cm. Water was
changed between testing of each rat. Vehicle or NPS
was injected 45 min before the test session. The
depression-related behaviours including, struggling,
swimming and ﬂoating during the 5 min on day 2
were blindly assessed according to previously de-
scribed methods (Cryan et al. 2002).
Home-cage locomotor activity
In randomly selected animals, home-cage activity was
measured 3–5 d after FST. The TSE Actimot system
(Germany) was used. Brieﬂy, following vehicle or NPS
injection, each rat was returned to its home cage,
which was subsequently placed inside the Actimot
counting chamber for 2 h. The chamber consists of an
aluminium frame equipped with infrared light beams,
allowing continuous measurement of the animal’s ac-
tivity.
Tissue preparation
Separate groups of naive male FSL, FRL and SD rats
were euthanized by decapitation (11:00–13:00 hours),
the brains were quickly removed and frozen in a
mixture of dry-ice and isopentane and, subsequently,
cut (200-mm-thick slices) on a cryostat. The left and
right hippocampi, amygdalae, and PVN were pun-
ched out using a brain puncher with an internal di-
ameter of 1 mm (Stoelting, USA). The brain samples
were stored in RNAse-free tubes at x80 xC until fur-
ther analysis.
Measurements of mRNA transcripts with real-time
quantitative polymerase chain reaction (real-time
qPCR)
RNA extraction was performed with RNeasy Mini kit
(Germany). RNA characterization, cDNA synthesis,
and real-time qPCR were performed as described
previously (Elfving et al. 2008).
Brieﬂy, the punched tissue were homogenized in
lysis buﬀer (Qiagen, Germany) with a mixer-mill
(Retsch, Germany; twice for 40 s at 30 Hz/s). Total
RNA was isolated following the manufacturer’s in-
structions (Qiagen). Aliquots of the RNA solution
were taken for both RNA quantiﬁcation and quality
assessment.
The integrity of RNA and the RNA concentration
were determined with RNA StdSens microﬂuidic
chips using the Experion Automated Electrophoresis
System (Bio-Rad, USA). The RNA purity and the RNA
concentration were determined with a NanoDrop
spectrometer (Thermo Fisher Scientiﬁc, USA). To en-
sure the same RNA basal properties in the groups,
data on quality, concentration, and purity of the ex-
tracted RNA from the FRL, FSL, and SD groups were
compared with one-way ANOVA. Afterwards RNA
was reversely transcribed using random primers and
Superscript II Reverse Transcriptase (Invitrogen, USA)
according to the manufacturer’s instructions. The
cDNA samples were stored undiluted atx80 xC until
real-time qPCR analysis. They were diluted 1:30 with
DEPC water before being used as a qPCR template.
Real-time qPCR
The real-time qPCR reactions were performed in 96-
well PCR plates using an Mx3000P (Stratagene, USA)
and SYBR Green. The gene expressions of NPSR1 and
eight diﬀerent reference genes [18 s subunit ribosomal
RNA (18 s rRNA), b-actin (ActB), cyclophilin A (CycA),
glyceraldehyde-3-phosphate dehydrogenase (Gapd),
hydroxy-methylbilane synthase (Hmbs), hypoxanthine
guanine phosphoribosyl transferase 1 (Hprt1), ribo-
somal protein L13A (Rpl13A), tyrosine 3-mono-
oxygenase/tryptophan 5-monooxygenase activation
protein, zeta (Ywhaz) were investigated. The reference
genes were selected as previously described (Bonefeld
et al. 2008). The primers were designed and tested ac-
cording our previous work (Elfving et al. 2008), see
Table 1.
The primers were obtained from DNA Technology
A/S (Denmark). Each SYBR Green reaction (20 ml total
volume) contained 1x SYBR Green master mix (Bio-
Rad), 0.5 mM primer pairs, and 6 ml diluted cDNA. The
mixture was heated initially to 95 xC for 3 min in order
to activate hot-start iTaq DNA polymerase and then 40
cycles with denaturation at 95 xC for 10 s, annealing at
60 xC for 30 s, and extension at 72 xC for 60 s were
applied. To verify that only one PCR product was de-
tected the samples were subjected to a heat dis-
sociation protocol ; after the ﬁnal cycle of PCR, the
reactions were heat-denatured by increasing the tem-
perature from 60 xC to 95 xC. All samples and the
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standard curve were run in duplicate. A standard
curve was generated on each plate.
Data analysis and statistics
Gene expression normalization was performed
according to our recent work (Bonefeld et al. 2008;
Elfving et al. 2010; Wegener et al. 2010). Brieﬂy, we ﬁrst
measured mRNA levels for the eight reference genes.
Stability comparison of the expression of the reference
genes was then conducted with Normﬁnder software
(Andersen et al. 2004). Values for each individual test
gene were subsequently normalized with the optimal
reference genes, based on the Normﬁnder mathemat-
ical algorithm (Andersen et al. 2004). The diﬀerential
response to NPS within the FSL, FRL, or SD strains
was analysed using one-way ANOVA or Student’s
t test (GraphPad Prism 5.0 ; USA). When appropriate,
the ANOVA was followed by Bonferroni’s post-hoc
test. Intra-strain gender diﬀerences were assessed
using Student’s t tests. Diﬀerences were considered
signiﬁcant at p<0.05. Data in the ﬁgures are shown as
¡standard error of the mean (S.E.M.). The numbers of
animals in each group are provided in the ﬁgures.
Results
Anxiety-related behaviour of FSL, FRL, and SD male
and female rats in the EPM (Table 2)
The basal behaviour of male and female FSL/FRL and
SD rats in the EPM is shown in Table 2 (the same basal
values are also shown in Figs 1 and 2). We found no
diﬀerences in anxiety-related behaviour between the
FSL and FRL strains (both sexes), although in females,
a trend to higher anxiety-like behaviour, as estimated
by the percentage of open-arm exploration time
(%OA), was found in FSL compared to FRL rats
(p=0.08, t=1.86, d.f.=16, p=0.081). However, FSL
and FRL males showed signiﬁcantly less anxiety-like
behaviour than SD males, as reﬂected by diﬀerences in
the percentage of open-arm entries (%OAE) (F2,24=
3.31, p=0.05), %OA (F2,24=9.27, p<0.001) and full
entries into open arms (FE) (F2,24=3.63, p=0.04).
Similarly, female FRL animals showed less anxiety-
like behaviour compared to female SD rats, as in-
dicated by the signiﬁcantly lower %OA (F2,23=6.75,
p=0.005). Gender diﬀerences could only be identiﬁed
in FSL, but not FRL and SD, rats : FSL females showed
signiﬁcantly less anxiety-like behaviour compared to
FSL males as reﬂected by an increased %OAE (t=2.30,
d.f.=17, p=0.034).
Depression-related behaviour of FSL, FRL and SD
male and female rats in the FST (Table 2)
The basal behaviour of FSL, FRL and SD animals in the
FST (immobility) is shown in Table 2 (the same basal
values are also shown in Figs 3 and 4). A comparison
of the basal immobility conﬁrmed the previously re-
ported and expected diﬀerences between FSL and FRL
males (F2,29=4.04, p=0.02) with FSL males displaying
more depression-like behaviour compared to FRL rats
Table 1. The forward and reverse primers used in real-time PCR
Gene Sequence Base pair length
NPSR1 Forward CTGTTCTCCATCCCCACACT 228
Reverse GCAGTTGGAAATCACCGTCT
18 s rRNA Forward ACGGACCAGAGCGAAAGCAT 310
Reverse TGTCAATCCTGTCCGTGTCC
ActB Forward TGTCACCAACTGGGACGATA 165
Reverse GGGGTGTTGAAGGTCTCAAA
CycA Forward AGCACTGGGGAGAAAGATT 248
Reverse AGCCACTCAGTCTTGGCAGT
Gapd Forward TCACCACCATGGAGAAGGC 168
Reverse GCTAAGCAGTTGGTGGTGCA
Hmbs Forward TCCTGGCTTTACCATTGGAG 176
Reverse TGAATTCCAGGTGAGGGAAC
Hprt 1 Forward GCAGACTTTGCTTTCCTTGG 81
Reverse CGAGAGGTCC TTTTCACCAG
Rpl13A Forward ACAAGAAAAAGCGGATGGTG 167
Reverse TTCCGGTAATGGATCTTTGC
Ywhaz Forward TTGAGCAGAAGACGGAAGGT 136
Reverse GAAGCATTGGGGATCAAGAA
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(p<0.05). Moreover, there was a tendency for FRL
females to be less immobile than their FSL and SD
counterparts (F2,21=3.30, p=0.057). Regarding gender
diﬀerences, female rats of all three strains showed
lower depression-like behaviour compared tomale rats
as indicated by the lower immobility in female FSL
(t=3.67, d.f.=21, p=0.0014), FRL (t=2.62, d.f.=12,
p=0.023) and SD (t=2.12, d.f.=17, p=0.049) rats.
Eﬀects of NPS on anxiety-like behaviour on the EPM
in FSL, FRL and SD rats
Males (Fig. 1)
As expected, NPS had a dose-dependent anxiolytic-
like eﬀect in all three rat strains when tested on the
EPM. The eﬀect was most pronounced in SD males,
where diﬀerences were found in %OAE (F2,21=32.32,
p<0.0001), %OA (F2,21=23.46, p<0.0001) and FE
(F2,21=7.26, p=0.004), with no eﬀect on CAE
(F2,21=3.22, p=0.06), although it may be considered
a trend. Bonferroni’s post-hoc analysis revealed a
dose-dependent increase in %OAE, %OA and FE
after NPS, when compared to vehicle-treated con-
trols.
NPS also aﬀected anxiety-related behaviour in FSL
male rats, speciﬁcally %OA (F3,41=8.21, p=0.0002)
and FE (F3,41=5.52, p=0.028), but no diﬀerences
in %OAE (F3,41=2.07, p=0.11) and CAE (F3,41=1.67,
p=0.13). Bonferroni’s post-hoc analysis revealed a
dose-related increase in %OAE and FE after NPS
Table 2. Basal behavioural values as measured in the elevated plus-maze (EPM) and forced swim test (FST)
Parameter
Males Females
FSL FRL SD FSL FRL SD
%OAE 41.91¡1.64 44.81¡6.88 36.38¡1.72a 50.63¡3.86d 49.63¡4.35 39.64¡3.15
%OA 41.60¡2.56 37.81¡6.89 19.80¡2.81ab 38.51¡6.78 56.58¡6.77 23.76¡5.29c
CAE 11.27¡1.05 11.43¡1.57 11.89¡1.36 7.75¡0.88e 9.10¡1.09 10.13¡0.83
FE 3.46¡0.42 2.14¡0.55 1.89¡0.46a 3.38¡0.94 4.10¡1.07 2.13¡0.67
Immobility 125.3¡10.76 77.14¡16.07 88.64¡13.50 58.57¡11.99e 22.14¡13.53d 56.20¡7.98d
%OAE, Percentage open-arm entries ; %OA, percentage time spent on open arm; CAE, closed-arm entries ; FE, full entries.
Values shown are means¡S.E.M.
a p<0.05 SD vs. FSL males ; b p<0.05 SD vs. FRL males ; c p<0.05 SD vs. FRL females (one-way ANOVA, Boferroni’s post-hoc) ;
d p<0.05 gender diﬀerence ; e p<0.01 gender diﬀerence (Student’s t test).
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Fig. 1. The eﬀect of diﬀerent doses (in nmol/5 ml) of NPS on male elevated plus-maze behaviour in FSL, FRL, and SD rats. Data
represent mean¡S.E.M. Two-way ANOVA, post-hoc Bonferroni’s correction were performed (* p<0.05, ** p<0.01, *** p<0.001).
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(eﬀective from 0.25 nmol/5 ml), when compared to
vehicle-treated controls.
NPS also aﬀected anxiety in FRL male rats, speciﬁ-
cally FE (F2,17=3.29, p=0.05), whereas %OA (F2,17=
2.02, p=0.16), %OAE (F2,17=0.84, p=0.44) and CAE
(F2,17=1.36, p=0.28) were not altered.
Females (Fig. 2)
An anxiolytic eﬀect of NPS was also revealed in female
rats, but this eﬀect was strain-dependent. Speciﬁcally,
in FSL females (Fig. 2, top panels), NPS (1 nmol/5 l)
caused an increase in %OA (t=2.95, d.f.=7, p=0.021),
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Fig. 2. The eﬀect of NPS (1 nmol/5 ml) on female elevated plus-maze behaviour in FSL, FRL and SD rats. Data represent
mean¡S.E.M. Student’s t test was performed (* p<0.05).
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Fig. 3. The eﬀect of diﬀerent doses (in nmol/5 ml) of NPS on male forced swim test behaviour in FSL, FRL, and SD rats. Data
represent mean¡S.E.M. Two-way ANOVA and post-hoc Bonferroni’s correction were performed. No diﬀerences were observed.
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but also inﬂuenced FE (t=2.92, d.f.=9, p=0.016)
compared to control. In contrast, in FRL females (Fig. 2,
middle panels), NPS (1 nmol/5 ml) only tended to in-
crease the number of FE (t=1.82, d.f.=11, p=0.095)
reﬂecting reduced anxiety, but failed to alter %OA
(t=0.09, d.f.=9, p=0.93) and %OAE (t=0.75, d.f.=11,
p=0.46).
Similarly, in SD females, NPS (1 nmol/5 ml) only
tended to increase the number of FE (t=1.425,
d.f.=15, p=0.17), but did not aﬀect %OAE (t=0.073,
d.f.=15, p=0.94) or %OA (t=0.315, d.f.=13, p=0.76)
compared to vehicle-treated controls.
NPS also altered locomotor activity, particularly
in female FSL rats where it increased CAE (t=2.16,
d.f.=9, p=0.028). In contrast, in FRL and SD female
rats, NPS only tended to increase locomotion
(FRL: t=1.745, d.f.=15, p=0.102; SD: t=1.582,
d.f.=15, p=0.14).
Eﬀects of NPS on depression-like behaviour in the
FST in FSL, FRL and SD rats
Males (Fig. 3)
Neither the high nor the low NPS dose modiﬁed
any of the three components of depressive-like be-
haviour (struggle, swimming, immobility) in FSL,
FRL, or SD male rats (Fig. 3). However, in SD rats, a
diﬀerence in the dataset for immobility was observed
(F3,21=3.53, p=0.03). The highest NPS dose tended
to reduce immobility ; however, post-hoc testing
did not reveal signiﬁcant diﬀerences between the
groups.
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Fig. 4. The eﬀect of NPS (1 nmol/5 ml) on female forced swim test behaviour in FSL, FRL and SD rats. Data represent
mean¡S.E.M. Student’s t test was performed (* p<0.05, ** p<0.01).
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Females (Fig. 4)
In agreement with the ﬁndings in male FSL and SD
animals, no overall eﬀect of NPS (1 nmol/5 ml) on FST
behaviours was observed in FSL or SD females.
However, in FRL females, NPS resulted in a signiﬁcant
increase in swimming (t=3.61, d.f.=14, p=0.002) and
a decrease in struggling behaviour (t=2.58, d.f.=14,
p=0.028).
Eﬀects of NPS on home-cage locomotion in FSL
rats (Fig. 5)
Home-cage activity of FSL was recorded for 120 min
directly following NPS infusion (Fig. 5). The percent-
age of activity/time was found to be altered in male
FSL rats treated with NPS at 0.5 and 1 nmol/5 ml
(F2,120=59.77, p<0.0001). Bonferroni’s post-hoc analysis
revealed a signiﬁcant diﬀerence between all groups
(p<0.001), and NPS increased locomotion in a dose-
dependent fashion.
Expression of NPSR1 in hippocampus, amygdala,
and PVN (Fig. 6)
Figure 6 shows the NPSR1 receptor mRNA copy
number as measured in the hippocampus, amygdala,
and PVN in naive male FSL, FRL, and SD animals. No
diﬀerence in the expression pattern was evident in any
of the areas, although a trend towards lower NPSR1
expression in FSL rats in the amygdala was found
(F2,22=1.94, p=0.16), and a simple comparison only
between FSL and FRL rats using unpaired t test re-
vealed a signiﬁcant increase in NPSR1 receptor mRNA
copy number in FRL male rats compared to FSL males
(t=2.22, d.f.=13, p=0.045).
Discussion
The main ﬁnding in the present work is the marked
dose-dependent anxiolytic eﬀect of NPS in male FSL,
FRL, and SD rats without any eﬀect on the depression-
related parameters in any strain assessed. In contrast,
while NPS was anxiolytic in female FSL and SD rats, it
did not alter anxiety-related behaviour in female FRL
rats. These results are in line with the previously re-
ported anxiolytic action of NPS in male mice and rats,
i.e. centrally administered NPS increased the time ani-
mals spent exploring the less protected or brighter
areas of their respective environment (open ﬁeld, four-
plate test, EPM, elevated zero-maze, light-dark box)
(Leonard et al. 2008; Rizzi et al. 2008; Xu et al. 2004) and
extend them to female rodents for the ﬁrst time. In
addition, an overall anxiolytic-like eﬀect of NPS has
also been demonstrated, as NPS reduced the time mice
spent burying unfamiliar objects (defensive marble-
burying test) (Vitale et al. 2008; Xu et al. 2004). The
reduction in anxiety-related behaviour after i.c.v. NPS
was particularly pronounced in FSL and SD male rats,
but not in FRL rats, demonstrating that the anxiolytic
properties of NPS may indeed be dependent on the
genetic background of the animals (Slattery et al. 2008;
Wegener et al. 2008).
Of note, the basal behaviour in the EPM was similar
in FSL and FRL strains whereas SD male and female
rats displayed more anxiety-related behaviour than
both Flinders strains. This result is in agreement with
previous work (Schiller et al. 1991). and is of interest
since it clearly separates the depressive-like and
anxiety-like phenotypes Consistent with such reason-
ing and in line with the evidence that FSL is a good
model of depression but not anxiety, administration of
diazepam equally increased the time FSL and FRL rats
spent in the open arms of the EPM (Overstreet et al.
1995). Young FSL rats (PND 40) display less anxiety in
the open ﬁeld and EPM compared to SD controls
(Braw et al. 2006), as was also observed in the present
study using adult rats. We are not aware of other
studies directly comparing the anxiety status of FSL
with SD controls, but the ﬁnding clearly highlights the
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Fig. 6. Expression of NPSR1 in (a) hippocampus, (b) amygdala and (c) PVN of male FSL, FRL SD rats displayed as mRNA copy
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FSL/FRL model exclusively as a model of depression.
This feature of the FSL indicates that the model also
has a heuristic value in exploring the neurobiology of
depression vs. anxiety, e.g. as shown in diﬀerences in
neuropeptide Y expression in FSL and HAB strains,
which display high anxiety and comorbid depression
(Mathe´ et al. 2006). Further, HAB mice display anxiety
without comorbid depression (Bunck et al. 2009).
As far as we are aware, this study is the ﬁrst to in-
vestigate gender diﬀerences in anxiety-like behaviour
between FSL and FRL animals, and gender-dependent
eﬀects of NPS. Therefore, the observation that FSL, but
not FRL or SD females, present with increased anxiety-
like behaviour in the EPM compared to their male
counterparts is a novel and intriguing ﬁnding (see
Table 2). However, the underlying mechanism(s)
remains unresolved and this ﬁnding needs to be re-
peated in order to strengthen its reliability as a genuine
characteristic of the FSL phenotype.
Interestingly, NPS exerted diﬀerential anxiolytic-
like eﬀects in male and female FSL, FRL and SD rats,
whereas anxiolytic eﬀects were found in male rats of
all three strains, signiﬁcant eﬀects on anxiety levels
could only be found in female FSL rats (Fig. 2). These
gender-dependent eﬀects of NPS are important for
the development of further therapeutic strategies.
However, the NPS eﬀect was comparatively weak in
FRL rats, and only detectable in the number of full
entries into the open arms, whereas the %OA time and
%OAE, the main established parameter of anxiety-
related behaviour on the EPM, were unaﬀected by
NPS. The neurobiological substrate underlying this
ﬁnding remains obscure, but recent studies suggest
that the amygdala is the core brain area responsible for
NPS-mediated anxiolytic-like actions (Jungling et al.
2008; Meis et al. 2008; Xu et al. 2004), and strain dif-
ferences regarding the amygdala response to NPS may
underlie this result. Interestingly, our real-time qPCR
results showed a trend for increased amygdala NPSR1
expression in male FRL compared to FSL rats. In ad-
dition, NPS produced a robust anxiolytic-like eﬀect
in male SD rats whereas this strain was shown to
have intermediate levels of NPSR1 compared to FSL
and FRL strains. Furthermore, the expression levels
of NPSR1 in amygdala did not show a correlation with
the behaviours in the EPM (data not shown).
NPS produced a signiﬁcant hyperlocomotion in
both male animals, when the home-cage locomotion
activity was assessed during 2 h following i.c.v. injec-
tion of NPS. This is a conﬁrmation of previous data,
demonstrating that NPS increases arousal as indicated
by hyperlocomotion, righting reﬂex and wakefulness
(Leonard et al. 2008; Rizzi et al. 2008; Xu et al. 2004).
In support, increased locomotor activity, as reﬂected
by the increased number of entries into the closed
arms of the EPM, was found in female rats, which
reached statistical signiﬁcance in female FSL rats.
Therefore, it may be hypothesized that the anxiolytic-
like eﬀects of NPS are related to increased arousal.
However, this ﬁnding does not agree with the ﬁnding
that the CAE in the EPM, which is considered an in-
dicative parameter of locomotion (Walf & Frye, 2007),
were not aﬀected by NPS in the three male strains
tested. Thus, it is possible that NPS exerts its arousing
eﬀects only under non-stressful circumstances, i.e.
in the home cage. This further suggests a speciﬁcity of
the anxiolytic eﬀect over locomotor eﬀects. These re-
sults are of note, since they clearly separate eﬀects of
NPS from those of the classical antidepressants, both
the tricyclics and the SSRIs, which are also anxiolytics.
Moreover, our ﬁnding strengthens the suggestion that
NPS agonists could be usable as a focused treatment
for anxiety.
Epidemiological and clinical studies have shown a
high degree of comorbidity between anxiety disorders
and depression (Judd et al. 1998; Wittchen et al. 1994),
and antidepressants are used routinely to treat symp-
toms of anxiety. It was, therefore, relevant to determine
whether the behavioural eﬀects of NPS also include
antidepressant-like activity. Consistent with previous
results, FSL rats compared to FRL rats showed greater
immobility in the FST, conﬁrming the well docu-
mented phenotype diﬀerences (El Khoury et al. 2006;
Overstreet et al. 2005; Yadid et al. 2000). An interesting
ﬁnding in the current study is that female FSL, FRL,
and SD rats consistently showed reduced depression-
like behaviour in the FST compared to their male
counterparts (see Table 2). Similarly, a previous study
reported decreased immobility in the FST for female
FSL rats compared to FSL males (Kokras et al. 2009),
whereas the same study found the opposite to be the
case for SD rats. Furthermore, and similar to our re-
sults, other groups have found lower immobility in
female Long-Evans (Mourlon et al. 2010) and Wistar
(Barros & Ferigolo, 1998) rats compared to males.
Together, these sex diﬀerences emphasize the impor-
tance of including both female and male subjects when
evaluating depression-like behaviour using the FST.
Of note, NPS failed to inﬂuence depression-like be-
haviour in any of the doses given. This is in agreement
with a previous study where NPS had anxiolytic-like
eﬀects, but did not inﬂuence the depression-like be-
haviour of mice in the tail suspension test (Leonard
et al. 2008). In a recent review, a similar, but unpub-
lished observation by Rizzi et al. using the FST is cited
(Guerrini et al. 2009). The current study extends these
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ﬁndings and demonstrates that NPS does not reduce
depression-like behaviour in FSL rats, a genetic animal
model of depression. In analogy to the anxiolytic-like
eﬀects, it was expected that hyperlocomotion follow-
ing NPS administration would also enhance mobility
in the FST. However, this was not observed, again
suggesting that the arousing eﬀects of NPS adminis-
tration are more observable in non-stressful situations.
The brain structures and physiological mechanisms
underlying the eﬀects of NPS observed here remain to
be established. Previously, it was reported that NPSR
mRNA is expressed in several distinct brain areas
related to stress responses, including amygdala, bed
nucleus of the stria terminalis, hypothalamus, raphe
nucleus, and ventral tegmental area (Leonard & Ring,
2011 ; Xu et al. 2004). However, in relation to a possible
eﬀect on depression-related parameters, it is relevant
to emphasize that the density of NPSR is very low in
hippocampus (Leonard & Ring, 2011 ; Xu et al. 2004), a
structure of importance in depression (Lee et al. 2002;
Videbech & Ravnkilde, 2004) and the FST (Airan et al.
2007). It is tempting to speculate that the absence of
antidepressant properties of NPS is due to this distinct
pattern in the regional NPSR expression.
In conclusion, our results conﬁrm the FSL line solely
as an animal model of depression and we demonstrate
speciﬁc gender diﬀerences in this genetic model
regarding behaviour in both the EPM and FST. In
addition, we conﬁrm that central NPS administration
is anxiolytic and we extend this ﬁnding to a psycho-
pathological animal model. Moreover, our data sug-
gests that NPS may mediate distinct neurobiological
aspects of anxiety in a gender-dependent way and can
discriminate between anxiety and depression pheno-
types.
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